CARBONIC ANHYDRASE INHIBITOR SUSTAINED RELEASE INTRAOCULAR DRUG DELIVERY SYSTEMS
First Claim
1. A sustained release intraocular drug delivery system comprising:
- a therapeutic component which is a carbonic anhydrase inhibitor, and;
a polymeric component associated with the therapeutic component to permit the therapeutic component to be released into the interior of an eye of an individual at a therapeutically effective dosage for a period of time after the drug delivery system is placed in the eye.
1 Assignment
0 Petitions
Accused Products
Abstract
Biocompatible intraocular drug delivery systems include a carbonic anhydrase inhibitor therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of implants or microparticles, and combinations thereof. The therapeutic agent is released in a biologically active form, for example, the therapeutic agent may retain its three dimensional structure when released into an eye of a patient, or the therapeutic agent may have an altered three. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.
-
Citations
23 Claims
-
1. A sustained release intraocular drug delivery system comprising:
-
a therapeutic component which is a carbonic anhydrase inhibitor, and; a polymeric component associated with the therapeutic component to permit the therapeutic component to be released into the interior of an eye of an individual at a therapeutically effective dosage for a period of time after the drug delivery system is placed in the eye. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)
-
Specification